nach oben

04.05.2024 | Original Article

Plasminogen activator inhibitor-1 is involved in glucocorticoid-induced decreases in angiogenesis during bone repair in mice

verfasst von: Kiyotaka Okada, Yuto Niwa, Kazusa Fukuhara, Takashi Ohira, Yuya Mizukami, Naoyuki Kawao, Osamu Matsuo, Hiroshi Kaji

Erschienen in: Journal of Bone and Mineral Metabolism

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Glucocorticoids delay fracture healing and induce osteoporosis. Angiogenesis plays an important role in bone repair after bone injury. Plasminogen activator inhibitor-1 (PAI-1) is the principal inhibitor of plasminogen activators and an adipocytokine that regulates metabolism. However, the mechanisms by which glucocorticoids delay bone repair remain unclear.

Materials and methods

Therefore, we herein investigated the roles of PAI-1 and angiogenesis in glucocorticoid-induced delays in bone repair after femoral bone injury using PAI-1-deficient female mice intraperitoneally administered dexamethasone (Dex).

Results

PAI-1 deficiency significantly attenuated Dex-induced decreases in the number of CD31-positive vessels at damaged sites 4 days after femoral bone injury in mice. PAI-1 deficiency also significantly ameliorated Dex-induced decreases in the number of CD31- and endomucin-positive type H vessels and CD31-positive- and endomucin-negative vessels at damaged sites 4 days after femoral bone injury. Moreover, PAI-1 deficiency significantly mitigated Dex-induced decreases in the expression of vascular endothelial growth factor as well as hypoxia inducible factor-1α, transforming growth factor-β1, and bone morphogenetic protein-2 at damaged sites 4 days after femoral bone injury.

Conclusion

The present results demonstrate that Dex-reduced angiogenesis at damaged sites during the early bone-repair phase after femoral bone injury partly through PAI-1 in mice.

Hofbauer LC, Minireview M, Rauner A (2009) Live and let die: molecular effects of glucocorticoids on bone cells. Mol Endocrinol 10:1525–1531CrossRef

McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205–2219CrossRefPubMed

Rhen T, Cidlowski JA (2005) Antiinflammatory action of glucocorticoids–new mechanisms for old drugs. N Engl J Med 353:1711–1723CrossRefPubMed

Strehl C, Buttgereit F (2013) Optimized glucocorticoid therapy: teaching old drugs new tricks. Mol Cell Endocrinol 380:32–40CrossRefPubMed

Hachemi Y, Rapp AE, Picke AK, Weidinger G, Ignatius A, Tuckermann J (2018) Molecular mechanisms of glucocorticoids on skeletal and bone regeneration after fracture. J Mol Endocrinol 61:R75-90CrossRefPubMedPubMedCentral

Henneicke H, Gasparini SJ, Brennan-Speranza TC, Zhou H, Seibel MJ (2014) Glucocorticoids and bone: local effects and systemic implications. Trends Endocrinol Metab 25:197–211CrossRefPubMed

Moutsatsou P, Kassi E, Papavassiliou AG (2012) Glucocorticoid receptor signaling in bone cells. Trends Mol Med 18:348–359CrossRefPubMed

Okada K, Okamoto T, Okumoto K, Takafuji Y, Ishida M, Kawao N, Matsuo O, Kaji H (2020) PAI-1 is involved in delayed bone repair induced by glucocorticoids in mice. Bone 134:115310CrossRefPubMed

Okada K, Kawao N, Nakai D, Wakabayashi R, Horiuchi Y, Okumoto K, Kurashimo S, Takafuji Y, Matsuo O, Kaji H (2022) Role of macrophages and plasminogen activator inhibitor-1 in delayed bone repair induced by glucocorticoids in mice. Int J Mol Sci 23:478CrossRefPubMedPubMedCentral

10.

Chen M, Li Y, Huang X, Gu Y, Li S, Yin P, Zhang L, Tang P (2021) Skeleton-vasculature chain reaction: a novel insight into the mystery of homeostasis. Bone Res 9:21CrossRefPubMedPubMedCentral

11.

Claes L, Recknagel S, Ignatius A (2012) Fracture healing under healthy and inflammatory conditions. Nat Rev Rheumatol 8:133–143CrossRefPubMed

12.

Bahney CS, Zondervan RL, Allison P, Theologis A, Ashley JW, Ahn J, Miclau T, Marcuclo RS, Hankenson AD (2019) Cellular biology of fracture healing. J Orthop Res 37:35–50CrossRefPubMed

13.

Fusumbe AP, Ramasamy SK, Adams RH (2014) Coupling of angiogenesis and osteogenesis by a apecific vessel stbtype in bone. Nature 507:323–328CrossRef

14.

Ramasamy SK, Kusumbe AP, Wang L, Adains RH (2014) Endothlial Notch activity promotes angiogenesis osteogenesis in bone. Nature 507:376–380CrossRefPubMedPubMedCentral

15.

Kawao N, Tamura Y, Okumoto K, Yano M, Okada K, Matsuo O, Kaji H (2013) Plasminogen plays a crucial role in bone repair. J Bone Miner Res 28:1561–1574CrossRefPubMed

16.

Kawao N, Tamura Y, Okumoto K, Yano M, Okada K, Matsuo O, Kaji H (2014) Tissue-type plasminogen activator deficiency delays bone repair: roles of osteoblast proliferation and vascular endothelial growth factor. Am J Physiol Endocrinol Metab 307:E278–E288CrossRefPubMed

17.

Kawao N, Tamura Y, Horiuchi Y, Okumoto K, Yano M, Okada K, Matsuo O, Kaji H (2015) The tissue fibrinolytic system contributes to the induction of macrophage function and CCL3 during bone repair in mice. PLoS ONE 10:e012398CrossRef

18.

Okada K, Kawao N, Tatsumi K, Ishida M, Takafuji Y, Kurashimo S, Okumoto K, Kojima K, Matsuo O, Kaji H (2018) Roles of plasminogen in the alterations in bone marrow hematopoietic stem cells during bone repair. Bone Reports 8:195–203CrossRefPubMedPubMedCentral

19.

Kaji H (2016) Adipose tissue-derived plasminogen activator inhibitor-I function and regulation. Comp Physiol 6:1873–1896CrossRef

20.

Mao L, Kawao N, Tamura Y, Okumoto K, Okada K, Yano M, Matsuo O, Kaji H (2014) Plasminogen activator inhibitor-1 is involved in impaired bone repair associated with diabetes in female mice. PLoS ONE 9:e92686CrossRefPubMedPubMedCentral

21.

Tamura Y, Kawao N, Okada K, Yano M, Okumoto K, Matsuo O, Kaji H (2013) Plasminogen activator inhibitor-1 is involved in streptozotocin-induced bone loss in female mice. Diabetes 62:3170–3179CrossRefPubMedPubMedCentral

22.

Mao L, Tamura Y, Kawao N, Okada K, Yano M, Okumoto K, Kaji H (2014) Influence of diabetic state and vitamin D deficiency on bone repair in female mice. Bone 61:102–108CrossRefPubMed

23.

Schipani E, Maes C, Carmeliet G, Semenza GL (2009) Regulation of osteogenesis-angiogenesis coupling by HIFs and VEGF. J Bone Miner Res 24:1347–1353CrossRefPubMedPubMedCentral

24.

Deckers MM, van Bezooijen RL, van der Horst G, Hoogendam J, van Der Bent C, Papapoulos SE, Lowik CW (2002) Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology 143:1545–1553CrossRefPubMed

25.

Bostrom K, Zebboudj AF, Yao Y, Lin TS, Torres A, Matrix GL (2004) A protein stimulates VEGF expression through increased transforming growth factor-beta1 activity in endothelial cells. J Biol Chem 279:52904–52913CrossRefPubMed

26.

Clifford RL, Deacon K, Knox AJ (2008) Novel regulation of vascular endothelial growth factor-A (VEGF-A) by transforming growth factor β1: requirement for Smads, β-catenin, and GSK3β. J Biol Chem 283:35337–35353CrossRefPubMed

27.

Langen UH, Pitulescu ME, Kim JM, Enriquez-Gasca R, Sivaraj KK, Kusumbe AP, Singh A, Di Russo J, Bixel MG, Zhou B, Sorokin L, Vaquerizas JM, Adams RH (2017) Cell-matrix signals specify bone endothelial cells during developmental osteogenesis. Nat Cell Biol 19:189–201CrossRefPubMedPubMedCentral

28.

Peng Y, Wu S, Li Y, Crane JL (2020) Type H blood vessels in bone modeling and remodeling. Theranostics 10:426–436CrossRefPubMedPubMedCentral

29.

Ramasamy SK, Kusumbe AP, Itkin T, Gur-Cohen S, Lapidot T, Adams RH (2016) Regulation of hematopoiesis and osteogenesis by blood vessel-derived signals. Annu Rev Cell Dev Biol 32:649–675CrossRefPubMed

30.

Karsenty G (2003) The complexities of skeletal biology. Nature 423:316–318CrossRefPubMed

31.

Peng Y, Shan L, Yusheng L, Jianxi Z, Shijie C, Gehua Z, Xu C, Song W, Janet LC (2020) Glucocorticoids disrupt skeletal angiogenesis through transrepression of NF-κB–mediated preosteoclast Pdgfb transcription in young mice. J Bone Miner Res 35:1188–1202CrossRefPubMed

32.

Xie H, Cui Z, Wang L, Xia Z, Hu Y et al (2014) PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat Med 20:1270–2127CrossRefPubMedPubMedCentral

33.

Kohara Y, Kitazawa R, Haraguchi R, Imai Y, Kitazawa S, Kaji H (2016) Macrophages are requisite for angiogenesis of type H vessels during bone regeneration in mice. Bone 154:116200CrossRef

34.

Harada K, Yahata T, Onizuka M, Ibrahim AA, Kikkawa E, Miyata T, Ando K (2021) Plasminogen activator inhibitor type-1 is a negative regulator of hematopoietic regeneration in the adipocyte-rich bone marrow microenvironment. Biochem Biophys Res Commun 557:180–186CrossRefPubMed

Titel: Plasminogen activator inhibitor-1 is involved in glucocorticoid-induced decreases in angiogenesis during bone repair in mice
verfasst von: Kiyotaka Okada
Yuto Niwa
Kazusa Fukuhara
Takashi Ohira
Yuya Mizukami
Naoyuki Kawao
Osamu Matsuo
Hiroshi Kaji
Publikationsdatum: 04.05.2024
Verlag: Springer Nature Singapore
Erschienen in: Journal of Bone and Mineral Metabolism
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-024-01510-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen